KarynVA
Crowing
Well, Merck, the company that manufactures ivermectin, was a shareholder in Moderna. Also, is making a version of the covid vaccine, itself.
Merck, which is also developing its own Covid-19 vaccines, was an early investor in Moderna, investing $50 million in 2015 and another $125 million in 2018. Moderna sold shares to the public for the first time in Dec. 2018. The U.S. drug giant said it had seen a large increase in the value of its investment since it first put money into the company.
“Merck achieved a substantial gain on its direct holding in MRNA over the life of the investment, particularly in 2020 given the substantial appreciation in MRNA’s stock price,” the drugmaker said in its statement
Merck still holds an indirect exposure to Moderna through its investment in venture funds, the company said, and the drugmakers are working together on developing new cancer therapies.
Anyone who thinks they are doing an end-run around Big Pharma by using ivermectin is sadly mistaken.
Merck, which is also developing its own Covid-19 vaccines, was an early investor in Moderna, investing $50 million in 2015 and another $125 million in 2018. Moderna sold shares to the public for the first time in Dec. 2018. The U.S. drug giant said it had seen a large increase in the value of its investment since it first put money into the company.
“Merck achieved a substantial gain on its direct holding in MRNA over the life of the investment, particularly in 2020 given the substantial appreciation in MRNA’s stock price,” the drugmaker said in its statement
Merck still holds an indirect exposure to Moderna through its investment in venture funds, the company said, and the drugmakers are working together on developing new cancer therapies.
Anyone who thinks they are doing an end-run around Big Pharma by using ivermectin is sadly mistaken.